Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Summary

The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma

Timeline

Start

2010-10

Primary completion

2011-09

Completion

2012-07

Outcome

Outcome not reported

Stopped (Business): “Financial/Business Reasons”

Drugs

Indications